Ovarian and Endometrial Cancer in Patients with Hereditary Non-polyposis Colorectal Cancer Syndrome

  • Kimberly Resnick
  • David Cohn
Part of the Cancer Genetics book series (CANGENETICS)


In this era of personalized medicine, genetic susceptibility to cancer is quickly becoming one of the most researched areas of the biomedical sciences. In addition, greater public understanding of the role that genes play in the development of cancer and potential testing requires that today’s physician be aware of these genetic predispositions, understand how to take a detailed family history, and be knowledgeable about the testing at his/her disposal. Hereditary non-polyposis colorectal cancer (HNPCC) is one such heritable, cancer susceptibility syndrome. The care of patients with this syndrome requires orchestrated efforts by gastroenterologists, gynecologists, surgeons, medical oncologists, and geneticists.


Endometrial Cancer Lynch Syndrome Endometrial Biopsy Mismatch Repair Gene Endometrial Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lynch H, Lynch JF. Lynch syndrome: history and current status. Dis Markers 2004; 20:181–98.PubMedGoogle Scholar
  2. 2.
    Necochea, R. From cancer families to HNPCC: Henry Lynch and the Transformations of Hereditary Cancer, 1975–1999. Bull Hist Med 2007; 81:267–285.CrossRefPubMedGoogle Scholar
  3. 3.
    Seiden MV, Patel D, O’Neill MJ, et al. Case Record of the Massachusetts General Hospital. Case 13-2007. A 46-year old woman with gynecologic and intestinal cancers. N Eng J Med 2007; 17:1760–9.Google Scholar
  4. 4.
    Taylor N, Mutch DG. Gynecologic manifestations of hereditary nonpolyposis colorectal cancer. From inherited to sporadic disease. Oncology (Williston Park) 2006; 1:85–94.Google Scholar
  5. 5.
    Wijnen J, de Leeuw W, Vasen H et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999; 23:142–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal acncer) among endometrial cancer patients. Cancer Res 2006; 15:7810–7.CrossRefGoogle Scholar
  7. 7.
    Hampel H, Panescu J, Lockman J, et al. (Comment on) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2007; 62:9603.Google Scholar
  8. 8.
    Karlan B, Berchuk A, Mutch D. The role of genetic testing for cancer susceptibility in gynecologic practice. Obstet Gynecol 2007; 110:155–167.CrossRefPubMedGoogle Scholar
  9. 9.
    Aarnio M, Mecklin JP, Aaltonen LA et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA mismatch repair genes. Int J Cancer 1999; 81:214–18.CrossRefPubMedGoogle Scholar
  11. 11.
    Vasen HFA, Mecklin JP, Meera Khan P et al. The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34:424–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Lipton LR, Johnson V, Cummings C et al. Refining the Amsterdam criteria and Bethesda guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 2004; 22:4934–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Syngal S, Fox EA, Li C. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer as mutations in MSH2 and MLH1. J Med Genet 2000; 9:641–5.CrossRefGoogle Scholar
  14. 14.
    Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105:569–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Vasen HFA, Watson P, Mecklin JP, et al. New clinical criteria for HNPCC proposed by ICG-HNPCC. Gastroenterology 1999; 116:1453–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Dunlop MG, Farrington SM, Carothers AD. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Gen 1997; 6:105–110.CrossRefPubMedGoogle Scholar
  17. 17.
    Lynch HT, Smyrk TC. Identifying hereditary nonpolyposis colorectal cancer. (editorial). N Eng J Med 1998; 338:1537.CrossRefPubMedGoogle Scholar
  18. 18.
    Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue is associated with hereditary nonpolyposis colorectal cancer. Nature 1994; 368:258.CrossRefPubMedGoogle Scholar
  19. 19.
    Song H, Ramus SJ, Quaye L, et al. Common variants of mismatch repair genes and risk of ovarian cancer. Carcinogenesis 2006; 27:2235–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Christmann M, Tomicic MT, Roos WP, et al. Mechanisms of human DNA repair: an update. Toxicology 2003; 193:3–34.CrossRefPubMedGoogle Scholar
  21. 21.
    de la Chapelle A. Microsatellite instability. N Eng J Med 2003; 349:209–210.Google Scholar
  22. 22.
    Boland CR, Thibodeau SN, Hamilton SR. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248–57.CrossRefGoogle Scholar
  23. 23.
    Vasen HFA, Hendriks Y, de Jong AE, et al. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers 2004; 20:207–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary non-polyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261–8.CrossRefGoogle Scholar
  25. 25.
    Cohn DE, Frankel WL, Resnick KE, et al. Improved outcomes with an intact DNA mismatch repair system in endometrial cancer: A tissue microarray study including correlation with surgicopathologic variables. Obstet Gynecol 2006; 108:1208–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Buttin B, Powell M, Mutch D, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microstaellite instability-positive endometrial carcinoma lacking MHL1 promoter methylation. Clin Can Res 2004; 10:481–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. PNAS 2003; 100:5908–13.CrossRefPubMedGoogle Scholar
  28. 28.
    Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 1:17–25.CrossRefGoogle Scholar
  29. 29.
    Buttin BM, Powell MA, Mutch DG, et al. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004; 74:1262–9.Google Scholar
  30. 30.
    Marsischky GT, Filosi N, Kane MF, et al. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 1996; 4:407–420.CrossRefGoogle Scholar
  31. 31.
    Halvarsson B, Lindblom A, Rambech E, et al. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam Cancer 2006; 5:353–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Chen PC, Dudley S, Hagen W, et al. Contributions by MutL homologues MLH3 and PMS2 to DNA mismatch repair tumor suppression in the mouse. Cancer Res 2005; 65:8662–70.PubMedGoogle Scholar
  33. 33.
    Taylor N, Powell M, Gibb R, et al. MLH3 mutation in endometrial cancer. Cancer Res 2006; 66:7502–08.CrossRefGoogle Scholar
  34. 34.
    Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 6870–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Cunningham JM, Christense ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in a colon cancer with microsatellite instability. Cancer Res 1998; 58:3455–60.PubMedGoogle Scholar
  36. 36.
    Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatelllite phenotype in sporadic endometrial cancers. Oncogen 1998; 17:2413–17.CrossRefPubMedGoogle Scholar
  37. 37.
    Gurin CC, Federici MG, Kang L, et al. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999; 2:462–66.CrossRefPubMedGoogle Scholar
  38. 38.
    Whelan AJ, Babb S, Mutch DG. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer 2002; 10:697–704.CrossRefPubMedGoogle Scholar
  39. 39.
    Duval A, Rolland S, Compoint A, et al. Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Hum Mol Gen 2001; 10:513–18.PubMedGoogle Scholar
  40. 40.
    Myeroff LL, Parsons R, Kim SJ. A transforming growth factor beta receptor type II mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995; 55:5545–7.PubMedGoogle Scholar
  41. 41.
    Woerner SM, Kloor M, Mueller A, et al. Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene 2005; 15:2525–35.PubMedGoogle Scholar
  42. 42.
    Tashiro H, Blazes M, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57:3935–40.CrossRefPubMedGoogle Scholar
  43. 43.
    Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 2006; 563–70.Google Scholar
  44. 44.
    Cohn D, Basil J, Venegoni A, et al. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 2000; 79:101–6.CrossRefGoogle Scholar
  45. 45.
    Konopka B, Janiec-Jankowska A, Czapczak. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and b-catenin (CTNNB1) gene mutations. J Cancer Res Clin Oncol 2007; 133:361–71.CrossRefGoogle Scholar
  46. 46.
    Duval A, Reperant M, Compoint A, et al. Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Res 2002; 62:1609–12.CrossRefPubMedGoogle Scholar
  47. 47.
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225–49.CrossRefPubMedGoogle Scholar
  48. 48.
    Bokhman JV. Two pathogenic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10–7.CrossRefGoogle Scholar
  49. 49.
    Fornasarig M, Campagnutta E, Talamini R, et al. Risk factors for endometrial cancer according to familial susceptibility. Int J Cancer 1998; 77:29–32.CrossRefGoogle Scholar
  50. 50.
    Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106:87–94.CrossRefGoogle Scholar
  51. 51.
    Cohn DE, Resnick KE, Morrison CD, et al. DNA mismatch repair and molecular alterations in non-endometrioid endometrial cancers. Gynecol Oncol 2006; Supplement: S2–S177.CrossRefGoogle Scholar
  52. 52.
    Maxwell GL, Risinger JI, Alvarez AA, et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001; 97:417–22.CrossRefPubMedGoogle Scholar
  53. 53.
    Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsattelite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Eng J Med 2003;349:247–57.CrossRefPubMedGoogle Scholar
  54. 54.
    Popat S, Huber R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23:609–18.CrossRefPubMedGoogle Scholar
  55. 55.
    Resnick KE, Frankel WD, Morrison CD, et al. An intact DNA mismatch repair system does not influence response to treatment with adjuvant chemotherapy or radiation in uterine cancer. A tissue microarray study in surgically staged patients. Gynecol Oncol 2006; Supplement: S2–S177.CrossRefPubMedGoogle Scholar
  56. 56.
    Domanska K, Malander S, Masback A, et al. Ovarian cancer at a young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer 2007; 17:789–93.CrossRefPubMedGoogle Scholar
  57. 57.
    Farrell C, Lyman M, Frietag K, et al. The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer. Genet Med 2006; 8:653–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Stratton JF, Thompson D, Bobrow L, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet 1999; 65:1725–32.CrossRefGoogle Scholar
  59. 59.
    Malander S, Rambech E, Kristoffersson U, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006; 101:238–43.CrossRefPubMedGoogle Scholar
  60. 60.
    Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82:223–8.Google Scholar
  61. 61.
    Geisler JP, Goodheart MJ, Sood AK, et al. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian cancer. Cancer 2003;98:2199–206.CrossRefPubMedGoogle Scholar
  62. 62.
    Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. Hereditary nonpoplyposis colorectal cancer. Cancer Genetics Studies Consortium,1997. JAMA 1997; 277:915–19.CrossRefPubMedGoogle Scholar
  63. 63.
    Levin, B, Barthel J, Burt R, et al. NCCN practice guidelines in oncology-colorectal cancer screening, 2007.Google Scholar
  64. 64.
    Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91:74–80.CrossRefPubMedGoogle Scholar
  65. 65.
    Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Eng J Med 2006; 19:261–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynceol 2007; 110:18–25.CrossRefPubMedGoogle Scholar
  67. 67.
    Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94:1708–12.CrossRefPubMedGoogle Scholar
  68. 68.
    Karlan BY, Berchuck A, Mutch D. The role of gynecologic testing for cancer susceptibility in gynecologic practice. Obstet Gynecol 2007; 110:155–67.CrossRefPubMedGoogle Scholar
  69. 69.
    Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296:1507–17.CrossRefPubMedGoogle Scholar
  70. 70.
    Sakaguchi J, Satoru K, Kanaya T et al. Aberrant expression and mutations of TGF-b receptor type II gene in endometrial cancer. Gynecologic Oncology 2005; 98:427–33.Google Scholar
  71. 71.
    Shia J, Klimstra DS, Nafa K et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutations in hereditary colorectal neoplasms. Am J Surg Path 2005; 1:96–104.CrossRefPubMedGoogle Scholar
  72. 72.
    Liu B, Nicolaides NC, Markowitz S et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995; 1:48–55.CrossRefPubMedGoogle Scholar
  73. 73.
    Vasen HFA, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis colorectal cancer). J Med Genet 2007; 44:353–362.Google Scholar
  74. 74.
    Lynch HT, Harris RE, Lynch PM, et al. Role of heredity in multiple primary cancer. Cancer 1977;40 (supp 4)1849–54.CrossRefPubMedGoogle Scholar
  75. 75.
    Mecklin JP, Jarvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis Col Rectum 1986; 29:160–4.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Gynecologic OncologyThe Ohio State University College of Medicine, James Cancer Hospital and Solove Research InstituteColumbusUSA

Personalised recommendations